Despite improvements in therapy, long-term mortality remains high in patients with heart failure and thus there remains a need for new treatment strategies to reduce the burden of mortality and morbidity associated with this condition. AT 1 -receptor blockers represent a rational approach to the management of heart failure, and have been shown to have beneficial effects on heart failure symptoms and exercise tolerance. However, the two outcome trials reported to date have not shown conclusive evidence of improvements in mortality. The potential benefits of AT 1 -receptor blockers in heart failure are currently being investigated in several trials. The CHARM programme (Candesartan in Heart failureAssessment of Reduction in Mortality and morbidity) is the largest heart failure trial so far. This comprises three
Introduction
Activation of the renin-angiotensin system plays a key role in the pathogenesis of heart failure. Angiotensin II, acting via AT 1 -receptors, causes vasoconstriction and sodium and water retention, which increase vascular resistance and impose a further load on the failing heart. 1 In addition, angiotensin II is implicated in the cardiovascular remodelling that occurs as an adaptive response to diminished cardiac output, and hence contributes to the progressive worsening of heart failure. 1 Clinical trials with angiotensin converting enzyme (ACE) inhibitors, in patients with a variety of cardiovascular disorders including hypertension, 2 congestive heart failure, [3] [4] [5] and acute myocardial infarction, 6 have clearly shown that blockade of the renin-angiotensin system reduces the burden of cardiovascular mortality and morbidity associated with heart failure. AT 1 -receptor blockade represents a new therapeutic approach, offering the potential for more specific and complete blockade of the renin-angiotensin system than can be achieved with ACE inhibitors. Rationale for use of AT 1 -receptor blockers in heart failure Despite the improvement in prognosis offered by ACE inhibitor therapy, mortality remains high in patients with heart failure. This is clearly illustrated by the long-term follow-up of patients included in one of the first trials with ACE inhibitors in heart failure, the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). 7 In the original double-blind phase of the trial, ACE inhibitor treatment was associated with a 46% reduction in 1-year mortality, compared with placebo; 83% of the patients then entered an extension phase during which all patients received open-label ACE inhibitor therapy. After 10 years, only five patients (all of whom were in the original ACE inhibitor group) of the 135 patients who entered the extension phase were still alive ( Figure 1) ; one patient was lost to follow-up. Such findings show that there remains a need for new treatment strategies to improve longterm outcome in heart failure During long-term ACE inhibitor treatment, plasma concentrations of angiotensin II eventually return to pretreatment levels in many patients. 8 This is at least partly due to the existence of alternative pathways of angiotensin II formation, involving enzymes such as chymase, 8, 9 that are not influenced by ACE inhibitors. Furthermore, since ACE inhibitors act by reducing angiotensin II formation, they unselectively inhibit all of the effects of angiotensin II, including potentially beneficial effects mediated via AT 2 -receptors. AT 1 -receptor blockers thus offer the advantage of selective blockade of the deleterious effects of AT 1 -receptor activation, independent of the source of angiotensin II, while allowing AT 2 -receptors to be stimulated.
A number of studies have investigated the effects of AT 1 -receptor blockers on exercise tolerance and symptoms in patients with heart failure. In one such study, 844 patients with New York Heart Association (NYHA) class II or III heart failure were randomised to receive candesartan cilexetil, 4 mg, 8 mg or 16 mg, or placebo for 12 weeks following a 4-week placebo run-in period. 10 Candesartan treatment produced a dose-dependent increase in total exercise time, compared with placebo, which was statistically significant with the highest dose ( Figure 2 ). Furthermore, all doses of candesartan produced significant improvements in heart failure symptoms, assessed by the Dyspnoea Fatigue Index.
In addition to blocking ACE, ACE inhibitors inhibit the breakdown of peptides such as bradykinin and substance P, and accumulation of these peptides is believed to lead to class-specific adverse effects such as cough. 11 Hence, AT 1 -receptor blockade may offer a superior tolerability profile, compared with ACE inhibitors. In the Study of Patients Intolerant of Converting Enzyme inhibitors (SPICE), 270 patients who had previously been found to be intolerant of ACE inhibitors were randomised to receive candesartan cilexetil, titrated from 4 mg to 16 mg once daily, or placebo for 12 weeks. 12 Intolerance to ACE inhibitors in these patients was most commonly due to cough (67%), hypotension (15%) and renal failure (11%). After 12 weeks, 82.7% of candesartan-treated patients were still receiving treatment, compared with 86.8% of patients in the placebo group; thus, candesartan was as well tolerated as placebo in these patients who were unable to tolerate ACE inhibitors. Furthermore, although the trial was too small to establish differences in outcome between the groups, there was a trend towards less progression of heart failure and rehospitalisation in the candesartan group.
The tolerability of AT 1 -receptor blockers and ACE inhibitors was compared directly in the second Evaluation of Losartan in the Elderly (ELITE II) Study. 13 In this study, 3152 patients with NYHA class II-IV heart failure were randomised to receive losartan, 50 mg once daily, or captopril, 50 mg three times daily, and followed for a median of 1.5 years. Overall, 14.7% of captopril-treated patients discontinued treatment because of adverse events, compared with 9.7% in the losartan group (P Ͻ 0.001). There were also significantly fewer withdrawals due to cough in the losartan group than in the ACE inhibitor group (0.3% vs 2.7%, P Ͻ 0.001).
Specific blockade of the renin-angiotensin system with AT 1 -receptor blockers thus represents a rational and potentially valuable approach to the management of heart failure. In addition, however, it is possible that combination therapy with AT 1 -receptor blockers and ACE inhibitors may be more effective than ACE inhibition alone, at least in some patients with heart failure. The rationale for this approach is based on the hypothesis that at least some of the beneficial effects of ACE inhibitors are attributable to vasodilator effects of bradykinin, 14 which as noted above accumulates during ACE inhibitor treatment. This possibility is currently being investigated in clinical trials.
Outcome studies with AT 1 -receptor blockers in heart failure
To date, two major outcome studies with AT 1 -receptor blockers in heart failure have been reported, and several others are in progress.
The ELITE II Study showed no significant difference in mortality rates between losartan-treated and captopril-treated patients. 13 The average annual allcause mortality rate in the losartan group was 11.7%, compared with 10.4% in the captopril group (P = 0.16). However, as described above, AT 1 -receptor blocker treatment was better tolerated than ACE inhibitor therapy. This study suggests, therefore, that AT 1 -receptor blockade may be similar in efficacy to ACE inhibition in heart failure patients, and significantly better tolerated.
The Valsartan Heart Failure Trial (Val-HeFT) involved 5010 patients with class II-IV heart failure, who were randomised to receive valsartan, 160 mg twice daily, or placebo, in addition to standard therapy that included ACE inhibitors and diuretics. 15 The primary outcome measures were time to death or time to first morbid event, which was defined as death, sudden death with resuscitation, hospitalisation for heart failure, or intravenous inotropic or vasodilator therapy for at least 4 h. There was no difference in all-cause mortality between the valsartan (19.7%) and placebo (19.4%) groups. There was, however, a significant reduction in all-cause mortality and morbidity in valsartan-treated patients, compared with the placebo group (28.8% vs 32.1%, respectively, risk reduction 13%; P = 0.009). The primary benefit was a 27% reduction in hospitalisations for heart failure in valsartan-treated patients (P = 0.00001). Subgroup analyses showed that the beneficial effects of AT 1 -receptor blockade were seen in both men and women, irrespective of age. The greatest benefits were seen among the 7% of patients who were not receiving treatment with ACE inhibitors; there was a trend towards a worse outcome in patients who received valsartan in addition to both ACE inhibitors and ␤-blockers. However, the results of these subgroup analyses require further investigation.
Further insights into the potential benefits of AT 1 -receptor blockers with respect to heart failure were obtained in the recent Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study. 16 This study involved 1513 patients with type 2 diabetes, who were randomised to receive losartan, 50-100 mg, or placebo in addition to their previous antihypertensive therapy. Although the study was not designed as a cardiovascular outcome study, a composite of cardiovascular morbidity and mortality was a pre-specified end point. AT 1 -receptor blockade was associated with a 32% reduction in the risk of first hospitalisation for heart failure, compared with placebo (P = 0.005). There was also a 28% reduction in the incidence of Journal of Human Hypertension myocardial infarction in the losartan group, but this did not reach statistical significance.
Continuing trials with AT 1 -receptor blockers in heart failure
A number of questions remain to be answered concerning the potential role of AT 1 -receptor blockers in heart failure.
(1) Are AT 1 -receptor blockers more effective than placebo? (2) Are AT 1 -receptor blockers more effective than ACE inhibitors? (3) Is a combination of an AT 1 -receptor blocker and an ACE inhibitor more effective than ACE inhibitor therapy alone?
These questions are currently being addressed in ongoing trials.
Are AT 1 -receptor blockers more effective than placebo?
AT 1 -receptor blockade and placebo are currently being compared in the Candesartan in Heart failure -Assessment of Reduction in Mortality and morbidity (CHARM) programme. 17 This programme, which will involve 7599 patients from 26 countries, comprises three studies (Figure 3 ):
• a study in patients with left ventricular systolic dysfunction (ejection fraction 40% or less), who are intolerant to ACE inhibitors (CHARM Alternative); • a study in patients with left ventricular systolic dysfunction who are also receiving ACE inhibitors (CHARM Added); • a study in patients with preserved left ventricular systolic function (ejection fraction Ͼ40%) (CHARM Preserved).
In each of these studies, patients have been randomised to receive candesartan cilexetil, titrated to 32 mg/day, or placebo, and will be followed for at least 2 years. While the primary end point for the overall CHARM programme is all-cause mortality, the primary end point in each of these trials will be a composite of cardiovascular mortality and hospitalisation for heart failure. The baseline characteristics and disease history of the patients recruited into these three trials are shown in Table 1 . A comparison of the patient populations included in the CHARM Added study with those in ELITE II and Val-HeFT shows that the patients included in the CHARM Added study tend to be more symptomatic (in terms of NYHA class), and include a higher proportion of patients treated with ␤-blockers or spironolactone than in the earlier trials. Similar trends are seen when patients in the CHARM Alternative Study are compared with those in ELITE II.
Two further trials are planned to investigate the efficacy of AT 1 -receptor blockers in patients with heart failure. In the HEAAL Study, 3240 symptomatic patients with chronic heart failure who are intolerant to ACE inhibitors will be randomised to receive losartan, 50 mg or 150 mg. The primary end point will be death or hospitalisation for heart failure. The results of this study are expected in 2006. The I-PRESERVE Study will involve patients with symptomatic heart failure and preserved left ventricular systolic function (ejection fraction Ͼ45%), who will be randomised to treatment with irbesartan or placebo. The primary endpoint will be a composite of death and hospitalisation for cardiovascular disease. This study is due to begin in 2002.
Are AT 1 -receptor blockers more effective than ACE inhibitors?
The ELITE II Study did not show a significant difference in mortality between patients treated with losartan, 50 mg, and those receiving ACE inhibitor therapy. 13 The effects of AT 1 -receptor blockers and ACE inhibitors are currently being compared in two trials, OPTIMAAL and VALIANT, involving patients with signs and symptoms of congestive heart failure following acute myocardial infarction.
The Optimal Trial In Myocardial infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) 18 involves 5476 patients who are randomised to receive losartan, 12.5-50 mg, or captopril, 12.5-50 mg three times daily; the primary end point is all-cause mortality. The results from this study will be presented in 2002.
In the Valsartan in Acute Myocardial Infarction (VALIANT) Study, 14485 patients are randomised to receive valsartan, 20-160 mg twice daily, captopril, 6.25-50 mg three times daily, or the two agents in combination. The results of this study are expected in 2003. Is a combination of an AT 1 -receptor blocker and an ACE inhibitor more effective than ACE inhibitor therapy alone?
In the Val-HeFT Study, described above, 93% of patients were receiving treatment with ACE inhibitors at the time of randomisation. In this study, the addition of valsartan had no significant effect on mortality, compared with placebo, although all-cause mortality and morbidity were significantly reduced. Moreover, as noted previously, the beneficial effect of valsartan on cardiovascular morbidity and mortality was most marked in patients who were not receiving ACE inhibitors; however, this finding was based on a subgroup analysis of a relatively small number of patients. The question of whether AT 1 -receptor blockade provides additional benefits when used in combination with ACE inhibition therefore remains to be answered conclusively.
More information regarding the potential benefits of combination therapy with AT 1 -receptor blockers and ACE inhibitors will be provided by the CHARM Added study with candesartan. As noted above, the patients included in this trial tend to be more symptomatic, in terms of NYHA class, than those in ValHeFT, and a higher proportion are receiving ␤-blockers or spironolactone. Furthermore, candesartan has been shown to provide more complete and prolonged blockade of the renin-angiotensin system than valsartan and other AT 1 -receptor blockers, [19] [20] [21] and thus may be expected to produce a greater clinical effect than that achieved with valsartan in Val-HeFT.
Conclusions
Despite the improvement in prognosis offered by ACE inhibitors, mortality and morbidity remain high in heart failure. More selective blockade of the reninangiotensin system with AT 1 -receptor blockers represents a new approach that may potentially improve outcome in patients with heart failure. There is as yet, however, no conclusive evidence from clinical trials that AT 1 -receptor blockers reduce cardiovascular mortality and morbidity in heart failure. As a result, current guidelines for the management of heart failure recommend that AT 1 -receptor blockers should be reserved for the relief of symptoms in patients who are unable to tolerate ACE inhibitors or ␤-blockers.
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Clinical trials currently in progress, in particular the CHARM Programme with candesartan, should provide important insights into the potential benefits of AT 1 -receptor blockers, and clarify the role of these agents in the management of heart failure.
